Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer

Source Link:: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=2152468

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ARRY

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Array will work with investigators to appropriately conclude the MILO study in a manner consistent with the best interest of each patient, while more detailed results will be shared with the scientific community in the future. All other ongoing studies of binimetinib, including the Phase 3 COLUMBUS (BRAF-mutant melanoma) and NEMO (NRAS-mutant melanoma) trials, are unaffected.

http://investor.arra...

Additional Relevant Details The decision to stop the study was made after a planned interim analysis showed that the Hazard Ratio for Progression Free Survival (PFS) crossed the predefined futility boundary. Top-line results from the study had been expected in 2017.

http://investor.arra...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Apr 01, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Milo Study, Ovarian Cancer, Nras-mutant Melanoma, Braf-mutant Melanoma, Encorafenib, Braf Inhibitor